Compare Healthcare Stocks

Compare Healthcare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., ABT, CVS, JNJ, LLY) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$125.67 -0.1%	$132.55	$99.92 ▼ $141.23	$218.92B	0.73	7.81 million shs	4.71 million shs
CVS CVS Health	$58.82 -4.9%	$64.65	$43.56 ▼ $72.51	$78.24B	0.57	6.23 million shs	12.43 million shs
JNJ Johnson & Johnson	$169.62 +0.3%	$155.75	$140.68 ▼ $169.99	$406.87B	0.41	8.40 million shs	6.63 million shs
LLY Eli Lilly and Company	$804.74 +0.7%	$770.86	$677.09 ▼ $972.53	$757.14B	0.4	2.83 million shs	2.78 million shs
NVS Novartis	$117.41 -0.5%	$117.43	$96.06 ▼ $124.83	$249.20B	0.59	1.82 million shs	2.31 million shs
PFE Pfizer	$25.37 +0.1%	$24.26	$20.92 ▼ $31.54	$144.18B	0.58	38.51 million shs	25.64 million shs
TDOC Teladoc Health	$8.20 -4.5%	$7.63	$6.35 ▼ $15.21	$1.51B	1.84	7.34 million shs	5.55 million shs
UNH UnitedHealth Group	$278.52 -4.8%	$301.79	$248.88 ▼ $630.73	$265.35B	0.45	11.55 million shs	22.50 million shs
RHHBY Roche	$41.44 +0.7%	$40.31	$34.10 ▼ $44.31	$262.39B	0.45	1.11 million shs	3.64 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	-0.08%	-4.55%	-5.60%	-2.77%	+21.05%
CVS CVS Health	+1.23%	-3.13%	-7.67%	-6.17%	+6.64%
JNJ Johnson & Johnson	+0.67%	+2.57%	+11.69%	+9.12%	+10.96%
LLY Eli Lilly and Company	+2.75%	+1.13%	+3.59%	-7.35%	-9.16%
NVS Novartis	+0.85%	-0.38%	+0.36%	+6.14%	+9.55%
PFE Pfizer	+0.79%	+2.99%	+5.34%	+11.07%	-14.13%
TDOC Teladoc Health	+1.39%	+8.35%	+8.28%	+17.99%	-8.02%
UNH UnitedHealth Group	+2.53%	+0.07%	-2.81%	-31.15%	-47.29%
RHHBY Roche	+2.26%	+2.34%	+2.75%	+3.50%	+7.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9869 of 5 stars	3.4	5.0	4.2	4.5	3.1	2.5	2.5
CVS CVS Health	4.9962 of 5 stars	3.5	5.0	3.3	3.9	2.8	3.3	3.8
JNJ Johnson & Johnson	4.7961 of 5 stars	2.3	4.0	4.2	3.9	3.4	1.7	1.9
LLY Eli Lilly and Company	4.9815 of 5 stars	4.4	4.0	3.3	4.0	3.9	1.7	1.9
NVS Novartis	1.7775 of 5 stars	1.0	3.0	2.5	0.0	3.3	0.0	1.9
PFE Pfizer	4.9784 of 5 stars	3.2	3.0	4.2	4.5	3.9	1.7	3.1
TDOC Teladoc Health	2.6446 of 5 stars	3.2	2.0	0.0	0.0	1.8	2.5	1.3
UNH UnitedHealth Group	4.9977 of 5 stars	4.3	5.0	4.2	4.0	3.3	3.3	2.5
RHHBY Roche	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.87	Moderate Buy	$144.47	14.96% Upside
CVS CVS Health	2.95	Moderate Buy	$75.13	27.72% Upside
JNJ Johnson & Johnson	2.65	Moderate Buy	$174.50	2.88% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,012.56	25.82% Upside
NVS Novartis	2.00	Hold	$123.67	5.33% Upside
PFE Pfizer	2.45	Hold	$28.55	12.52% Upside
TDOC Teladoc Health	2.37	Hold	$9.65	17.79% Upside
UNH UnitedHealth Group	2.58	Moderate Buy	$394.43	41.61% Upside
RHHBY Roche	2.57	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest Healthcare Stocks Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	JNJ Johnson & Johnson	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/22/2025	CVS CVS Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$71.00 ➝ $67.00
7/18/2025	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$147.00 ➝ $142.00
7/18/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$142.00 ➝ $141.00
7/18/2025	ABT Abbott Laboratories	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$148.00 ➝ $145.00
7/18/2025	ABT Abbott Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$143.00 ➝ $145.00
7/17/2025	UNH UnitedHealth Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
7/17/2025	UNH UnitedHealth Group	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/17/2025	JNJ Johnson & Johnson	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
7/17/2025	ABT Abbott Laboratories	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2025	JNJ Johnson & Johnson	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$165.00 ➝ $176.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.21	$6.58 per share	19.10	$27.62 per share	4.55
CVS CVS Health	$372.81B	0.20	$8.75 per share	6.72	$60.18 per share	0.98
JNJ Johnson & Johnson	$90.63B	4.50	$13.25 per share	12.80	$29.69 per share	5.71
LLY Eli Lilly and Company	$49.00B	15.56	$14.75 per share	54.55	$15.03 per share	53.54
NVS Novartis	$50.32B	4.93	$10.75 per share	10.92	$19.91 per share	5.90
PFE Pfizer	$63.63B	2.27	$4.41 per share	5.76	$15.62 per share	1.62
TDOC Teladoc Health	$2.57B	0.56	$5.43 per share	1.51	$8.66 per share	0.95
UNH UnitedHealth Group	$410.06B	0.62	$31.61 per share	8.81	$106.78 per share	2.61
RHHBY Roche	$68.73B	3.85	$3.39 per share	12.21	$6.44 per share	6.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	15.75	21.93	2.38	32.43%	18.83%	10.88%	N/A
CVS CVS Health	$4.61B	$4.19	14.04	8.69	0.87	1.39%	10.59%	3.17%	7/31/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$9.35	18.14	15.32	2.14	25.00%	33.07%	13.16%	N/A
LLY Eli Lilly and Company	$10.59B	$12.29	65.48	25.86	1.12	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
NVS Novartis	$11.94B	$6.87	17.09	13.33	1.65	25.64%	41.08%	16.83%	N/A
PFE Pfizer	$8.03B	$1.38	18.39	8.37	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
TDOC Teladoc Health	-$1.00B	-$5.92	N/A	N/A	N/A	-39.66%	-11.01%	-4.66%	7/29/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$23.88	11.66	8.38	1.39	5.39%	26.29%	8.67%	7/29/2025 (Estimated)
RHHBY Roche	$9.40B	N/A	0.00	13.81	3.21	N/A	N/A	N/A	7/24/2025 (Estimated)

Latest Healthcare Stocks Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.56	N/A	N/A	N/A	$14.40 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/31/2025	Q2 2025	CVS CVS Health	$1.45	N/A	N/A	N/A	$94.87 billion	N/A
7/29/2025	Q2 2025	TDOC Teladoc Health	-$0.24	N/A	N/A	N/A	$621.91 million	N/A
7/29/2025	Q2 2025	UNH UnitedHealth Group	$5.16	N/A	N/A	N/A	$111.75 billion	N/A
7/24/2025	N/A	RHHBY Roche	$1.62	$1.74	+$0.12	N/A	$15.33 billion	$40.12 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion
7/17/2025	Q2 2025	NVS Novartis	$2.38	$2.42	+$0.04	$2.06	$13.94 billion	$14.05 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion
5/1/2025	Q1 2025	CVS CVS Health	$1.62	$2.25	+$0.63	$1.41	$93.07 billion	$94.59 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.88%	N/A	29.57%	54 Years
CVS CVS Health	$2.66	4.52%	N/A	63.48%	4 Years
JNJ Johnson & Johnson	$5.20	3.07%	N/A	55.61%	64 Years
LLY Eli Lilly and Company	$6.00	0.75%	N/A	48.82%	11 Years
NVS Novartis	$2.60	2.21%	N/A	37.85%	N/A
PFE Pfizer	$1.72	6.78%	N/A	124.64%	16 Years
TDOC Teladoc Health	N/A	N/A	N/A	N/A	N/A
UNH UnitedHealth Group	$8.84	3.17%	N/A	37.02%	15 Years
RHHBY Roche	$0.87	2.10%	N/A	N/A	N/A

Latest Healthcare Stocks Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
7/7/2025	CVS CVS Health	quarterly	$0.6650	3.99%	7/22/2025	7/22/2025	8/1/2025
6/5/2025	UNH UnitedHealth Group	quarterly	$2.21	3%	6/16/2025	6/16/2025	6/24/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
CVS CVS Health	0.77	0.82	0.63
JNJ Johnson & Johnson	0.49	1.26	1.03
LLY Eli Lilly and Company	2.18	1.37	1.06
NVS Novartis	0.53	0.82	0.62
PFE Pfizer	0.64	1.26	0.96
TDOC Teladoc Health	0.70	1.68	1.64
UNH UnitedHealth Group	0.71	0.85	0.85
RHHBY Roche	0.85	1.48	1.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
CVS CVS Health	80.66%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
NVS Novartis	13.12%
PFE Pfizer	68.36%
TDOC Teladoc Health	76.82%
UNH UnitedHealth Group	87.86%
RHHBY Roche	N/A

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
CVS CVS Health	1.22%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%
NVS Novartis	0.01%
PFE Pfizer	0.06%
TDOC Teladoc Health	0.58%
UNH UnitedHealth Group	0.28%
RHHBY Roche	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
CVS CVS Health	300,000	1.27 billion	1.25 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
TDOC Teladoc Health	5,500	175.43 million	174.42 million	Optionable
UNH UnitedHealth Group	400,000	907.14 million	904.60 million	Optionable
RHHBY Roche	103,249	6.38 billion	N/A	Not Optionable

Healthcare Stocks Headlines

Recent News About These Companies

Roche pauses Sarepta gene therapy shipments outside the U.S.

1 hour ago | msn.com

Roche eyes direct-to-patient sales in U.S. to avoid pharma middlemen

July 24 at 4:43 PM | msn.com

Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results

July 24 at 4:43 PM | seekingalpha.com

Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well

July 24 at 11:50 AM | zacks.com

Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025

July 24 at 9:00 AM | prnewswire.com

Roche Holding AG: Hold Rating Amid Mixed Financial Signals and Strategic Challenges

July 24 at 7:07 AM | tipranks.com

Roche considering selling drugs directly to US patients, CEO says

July 24 at 6:03 AM | reuters.com

Roche confirms guidance as H1 core operating profit up 6%

July 24 at 2:37 AM | reuters.com

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025

July 24 at 2:00 AM | globenewswire.com

The Roche Associates, Inc. Named “Top Senior Living Marketing Agency 2025”

July 23 at 5:20 PM | globenewswire.com

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease

July 23 at 4:59 AM | manilatimes.netM

European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

July 23 at 4:59 AM | finance.yahoo.com

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

July 23 at 2:10 AM | globenewswire.com

European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

July 23 at 2:00 AM | globenewswire.com

EWL: Buy Swiss, Invest Globally

July 22 at 11:56 PM | seekingalpha.com

Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

July 22 at 6:55 PM | uk.finance.yahoo.com

Sarepta pares gains as report suggests an ‘arduous’ path for Duchenne drug

July 22 at 6:55 PM | msn.com

Roche pauses shipments of Elevidys gene therapy outside the US, Bloomberg News reports

July 22 at 5:42 PM | reuters.com

Roche's Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

July 22 at 12:45 PM | globenewswire.com

Roche COPD biologic astegolimab fails in phase 3 for COPD

July 21 at 3:52 PM | msn.com

Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Do They Know Something? Insiders & Congress Buy UnitedHealth
By Brian O'Connell | July 9, 2025
View Do They Know Something? Insiders & Congress Buy UnitedHealth
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
By Gabriel Osorio-Mazilli | July 23, 2025
View Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Falling Fast, Rising Soon? 3 Stocks With Upside Ahead
By Nathan Reiff | July 23, 2025
View Falling Fast, Rising Soon? 3 Stocks With Upside Ahead
Intuitive Surgical Crushes Q2 Expectations, So Why No Rally?
By Leo Miller | July 23, 2025
View Intuitive Surgical Crushes Q2 Expectations, So Why No Rally?
5 Robotics Stocks to Buy for the Future of Automation
By Ryan Hasson | July 14, 2025
View 5 Robotics Stocks to Buy for the Future of Automation

Healthcare Stocks Company Descriptions

Abbott Laboratories NYSE:ABT

$125.67 -0.16 (-0.13%)

Closing price 03:59 PM Eastern

Extended Trading

$125.43 -0.24 (-0.19%)

As of 07:57 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

CVS Health NYSE:CVS

$58.82 -3.03 (-4.90%)

Closing price 03:59 PM Eastern

Extended Trading

$58.93 +0.11 (+0.18%)

As of 07:59 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Johnson & Johnson NYSE:JNJ

$169.62 +0.52 (+0.31%)

Closing price 03:59 PM Eastern

Extended Trading

$169.66 +0.04 (+0.02%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$804.74 +5.85 (+0.73%)

Closing price 03:59 PM Eastern

Extended Trading

$803.88 -0.87 (-0.11%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novartis NYSE:NVS

$117.41 -0.56 (-0.48%)

Closing price 03:59 PM Eastern

Extended Trading

$117.41 +0.00 (+0.00%)

As of 05:53 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$25.37 +0.01 (+0.05%)

Closing price 03:59 PM Eastern

Extended Trading

$25.42 +0.04 (+0.17%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Teladoc Health NYSE:TDOC

$8.20 -0.39 (-4.49%)

Closing price 03:59 PM Eastern

Extended Trading

$8.26 +0.07 (+0.84%)

As of 07:57 PM Eastern

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

UnitedHealth Group NYSE:UNH

$278.52 -13.99 (-4.78%)

Closing price 03:59 PM Eastern

Extended Trading

$279.77 +1.25 (+0.45%)

As of 08:00 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Roche OTCMKTS:RHHBY

$41.44 +0.30 (+0.73%)

As of 04:00 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Healthcare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest Healthcare Stocks Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest Healthcare Stocks Earnings

Compare Dividends

Latest Healthcare Stocks Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

Healthcare Stocks Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Healthcare Stocks Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools